Arthneeti
Solara ActiveQ1 FY25

Solara Active Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹645.65P/E: 66.2Market Cap: ₹3.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

No

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
No information is provided regarding the same in the latest conference call.

See what Solara Active management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
No information is provided regarding the same in the latest conference call.

See what Solara Active management said on order book — free account, 30 seconds.

Capex plans

Yes
No information is provided regarding the same in the latest conference call.

Track Solara Active — get its next earnings analysis in your feed

How does Solara Active rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSolara Active
Rev 3Mar 3
See where Solara Active sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Solara Active rank in Pharmaceuticals & Biotechnology?

Compare Solara Active against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY27)

    Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj

  • Himalaya Nutravedics (Q2 FY27)

    Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese

  • Granules India (Q2 FY27)

    Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →